Cipla announced that the United States Food and Drug Administration (USFDA) has classified the inspection conducted at its Goa manufacturing facility from 16-27 September 2019 as Official Action Indicated (OAI).
The Company does not believe that this will have any material impact on the US business at this stage. The Company has a strong track record of maintaining the highest standard of compliance and will work closely with the agency to comprehensively address the observations received.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
